

# A phase I/II, double blind, cross-over design, placebo controlled, pilot study to assess the effect and tolerability of multiple oral doses of phytosphingosine in Sjögren's patients.

No registrations found.

<b>Ethical review</b>	Not applicable
<b>Status</b>	Recruitment stopped
<b>Health condition type</b>	-
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON25165

### Source

NTR

### Brief title

Oral Hygiene Xerostomia

### Health condition

Xerostomia, Sjogren disease, Candida albicans, phytosphingosine

## Sponsors and support

**Primary sponsor:** Section Oral & Maxillofacial Surgery

University Medical Center Groningen

Hanzeplein 1

9713 GZ Groningen

**Source(s) of monetary or material Support:** ZON-MW

Laan van Nieuw Oost Indië 334

2493 CE Den Haag

The Netherlands

Tel: 070 3495111

Fax: 070 3495100  
infp@zonmw.nl

## Intervention

## Outcome measures

### Primary outcome

Reduction in *C. albicans* and or *S. mutans* relative to control.

### Secondary outcome

Tolerability.

## Study description

### Background summary

N/A

### Study objective

N/A

### Study design

One hour treatment repeated crossed over after 14 days.

### Intervention

Single treatment with pastilles containing phytosphingosine or placebo. Wash out period at least 14 days.

## Contacts

### Public

Section Oral & Maxillofacial Surgery  
University Medical Center Groningen  
Hanzeplein 1

A. Vissink  
Section Oral & Maxillofacial Surgery  
University Medical Center Groningen  
Hanzeplein 1

Groningen 9713 GZ  
The Netherlands  
+31(0)50 3613841

**Scientific**

Section Oral & Maxillofacial Surgery  
University Medical Center Groningen  
Hanzeplein 1

A. Vissink  
Section Oral & Maxillofacial Surgery  
University Medical Center Groningen  
Hanzeplein 1

Groningen 9713 GZ  
The Netherlands  
+31(0)50 3613841

## Eligibility criteria

### Inclusion criteria

1. Primary Sjögren's syndrome female adult patients, diagnosed following EU criteria [1];
2. Stimulated whole salivary flow rate >0.30 ml/min, stimulated parotid salivary >0.15 ml/min;
3. Saliva positive for *S. mutants* and *C. albicans* (all m.o. cfu $\geq$ 10<sup>3</sup>);
4. Not pregnant;
5. No use of xerogenic drugs or drugs that might affect oral ecology;
6. Willing and able to adhere to the study visit schedule and other protocol requirements;
7. Written informed consent signed.

## Exclusion criteria

1. Use of antibiotic medication less than 3 weeks before screening;
2. Dentures;
3. Smoking;
4. Current or history of drug and/or alcohol abuse;
5. In parallel participation in another trial with an investigational product.

## Study design

### Design

Study type:	Interventional
Intervention model:	Crossover
Allocation:	Non controlled trial
<b>Control:</b>	Placebo

### Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	01-09-2009
Enrollment:	20
Type:	Actual

## Ethics review

Not applicable	
Application type:	Not applicable

## Study registrations

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

<b>Register</b>	<b>ID</b>
NTR-new	NL1769
NTR-old	NTR1879
Other	UMCG : PHS-01
ISRCTN	ISRCTN wordt niet meer aangevraagd.

## Study results

### Summary results

N/A